{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:45:49Z","timestamp":1782956749280,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T00:00:00Z","timestamp":1467763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T00:00:00Z","timestamp":1467763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate the mechanism underlying AT1-AA-induced retinopathy in severe preeclampsia by measuring the positive rate and titer of AT1-AA in plasma from women with severe preeclampsia and normal pregnant women to see whether AT1-AA titer was correlated with the grade of retinopathy. A preeclampsia rat model was also established by intravenous injection of AT1-AA extracted from the plasma of patient suffering from severe preeclampsia. The results showed that the plasma titer and positive rate of AT1-AA were significantly higher in women with severe preeclampsia than normal pregnant women. The antibody titer in cases of severe preeclampsia was associated with the grade of retinopathy, and positively correlated with the level of TNF-\u03b1 and VEGF. The animal experiment results showed that the modeled rats presented symptoms very similar to symptoms of human preeclampsia, including retinopathy. Ocular fundus examination showed retinal microvascular abnormalities, hemorrhaging and leakage in the severe preeclampsia. Morphological changes included edema, thickening of the INL and ONL, and pigment atrophy. TNF-\u03b1 and VEGF levels were increased in the vitreous humor and retina of the model rats. Our studies results suggest that abnormal expression of AT1-AA could induce damage to retinal capillary endothelial cells and increase vascular permeability, resulting in retinopathy.<\/jats:p>","DOI":"10.1038\/srep29036","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T09:06:12Z","timestamp":1467795972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Role of agonistic autoantibodies against type-1 angiotensin II receptor in the pathogenesis of retinopathy in preeclampsia"],"prefix":"10.1038","volume":"6","author":[{"given":"Fang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,6]]},"reference":[{"key":"BFsrep29036_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/jhh.2013.148","volume":"28","author":"J Xiao","year":"2014","unstructured":"Xiao, J. et al. Is ethnicity a risk factor for developing preeclampsia? An analysis of the prevalence of preeclampsia in China. J Hum Hypertens 28, 694\u2013698, 10.1038\/jhh.2013.148 (2014).","journal-title":"J Hum Hypertens"},{"key":"BFsrep29036_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1161\/HYPERTENSIONAHA.113.02293","volume":"63","author":"S Rana","year":"2014","unstructured":"Rana, S., Karumanchi, S. A. & Lindheimer, M. D. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 63, 198\u2013202, 10.1161\/HYPERTENSIONAHA.113.02293 (2014).","journal-title":"Hypertension"},{"key":"BFsrep29036_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/2320-3897.163264","volume":"3","author":"AJ Bhandari","year":"2015","unstructured":"Bhandari, A. J., Bangal, S. V. & Pratik, G. Ocular fundus changes in pre-eclampsia and eclampsia in a rural set-up. J Clin Ophthalmol Res 3, 139\u2013142 (2015).","journal-title":"J Clin Ophthalmol Res"},{"key":"BFsrep29036_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.sjopt.2012.04.003","volume":"27","author":"K Abu Samra","year":"2013","unstructured":"Abu Samra, K. The eye and visual system in the preeclampsia\/eclampsia syndrome: What to expect? Saudi J Ophthalmol 27, 51\u201353, 10.1016\/j.sjopt.2012.04.003 (2013).","journal-title":"J Ophthalmol"},{"key":"BFsrep29036_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/mol.115.099176","volume":"88","author":"T Takezako","year":"2015","unstructured":"Takezako, T., Unal, H., Karnik, S. S. & Node, K. Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor. Mol Pharmacol 88, 488\u2013501, 10.1124\/mol.115.099176 (2015).","journal-title":"Mol Pharmacol"},{"key":"BFsrep29036_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/aji.12340","volume":"73","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi, Y., Yamamoto, T., Chishima, F., Takahashi, H. & Suzuki, M. Autoantibodies isolated from patients with preeclampsia induce soluble endoglin production from trophoblastcells via interactions with angiotensin II type 1 receptor. Am J Reprod Immunol 73, 285\u2013291, 10.1111\/aji.12340 (2015).","journal-title":"Am J Reprod Immunol"},{"key":"BFsrep29036_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1161\/ CIRCRESAHA.113.300752","volume":"113","author":"Y Xia","year":"2013","unstructured":"Xia, Y. & Kellems, R. E. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res 113, 78\u201387, 10.1161\/ CIRCRESAHA.113.300752 (2013).","journal-title":"Circ Res"},{"key":"BFsrep29036_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/ nm.1856","volume":"14","author":"CC Zhou","year":"2008","unstructured":"Zhou, C. C. et al. Angiotensin receptor agonistic autoantibodies induce pre- eclampsiain pregnant mice. Nat Med 14, 855\u2013862, 10.1038\/ nm.1856 (2008).","journal-title":"Nat Med"},{"key":"BFsrep29036_CR9","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1161\/ HYPERTENSIONAHA. 110.150540","volume":"55","author":"RA Irani","year":"2010","unstructured":"Irani, R. A. et al. Autoantibody-mediated angiotensin receptor activation. Contributes to preeclampsia through tumor necrosis factor-alpha signaling. Hypertension 55, 1246\u20131253, 10.1161\/ HYPERTENSIONAHA. 110.150540 (2010).","journal-title":"Hypertension"},{"key":"BFsrep29036_CR10","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/abbs\/gms 087","volume":"44","author":"W Chai","year":"2012","unstructured":"Chai, W. et al. Angiotensin II type I receptor agonistic autoantibody- induced apoptosis in neonatal rat cardiomyocytes is dependent on the generation of tumor necrosis factor-\u03b1. Acta Biochim Biophys Sin 44, 984\u201390. 10.1093\/abbs\/gms 087 (2012).","journal-title":"Acta Biochim Biophys Sin"},{"key":"BFsrep29036_CR11","doi-asserted-by":"crossref","unstructured":"Jin, Z. et al. Maternal treatment with agonistic autoantibodies against type-1 angiotensin II receptor in late pregnancy increases apoptosis of myocardial cells and myocardial susceptibility to ischemia-reperfusion injury in offspring rats. PLOS ONE 8, e80709. 10.1371\/journal. pone.0080709 (2013)","DOI":"10.1371\/journal.pone.0080709"},{"key":"BFsrep29036_CR12","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1167\/iovs.10-5768","volume":"52","author":"H Huang","year":"2011","unstructured":"Huang, H. et al. TNF-\u03b1 is required for late BRB breakdown in diabetic retinopathy and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci 52, 1336\u20131344. 10.1167\/iovs.10-5768 (2011).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep29036_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal. 2015.06.004","volume":"60","author":"M Cordero-Coma","year":"2015","unstructured":"Cordero-Coma, M. & Sobrin, L. Anti-tumor necrosis factor-\u03b1 therapy in uveitis. Surv Ophthalmol 60, 575\u2013589, 10.1016\/j.survophthal. 2015.06.004 (2015).","journal-title":"Surv Ophthalmol"},{"key":"BFsrep29036_CR14","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1167\/iovs.11-7912","volume":"52","author":"R Robinson.","year":"2011","unstructured":"Robinson. R. et al. Fluvastatin down regulates VEGF-A expression in TNF-\u03b1- induced retinal vessel tortuosity. Invest Ophthalmol Vis Sci 52, 7423\u20137431, 10. 1167\/iovs.11-7912 (2011).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep29036_CR15","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1167\/iovs.09- 4890","volume":"51","author":"P Lichtlen","year":"2010","unstructured":"Lichtlen, P. et al. Relative contribution of VEGF and TNF-\u03b1 in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci 51, 4738\u20134745, 10.1167\/iovs.09- 4890 (2010).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep29036_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/01.RES.82.5.619","volume":"82","author":"A Otani","year":"1998","unstructured":"Otani, A., Takagi, H., Suzuma, K. & Honda, Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 82, 619\u2013628 (1998).","journal-title":"Circ Res"},{"key":"BFsrep29036_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000365865","volume":"5","author":"O Georgiadis","year":"2014","unstructured":"Georgiadis, O., Kabanarou, S. A., Batsos, G., Feretis, E. & Xirou, T. Bilateral hypertensive retinopathy complicated with retinal neovascularization: panretinal photocoagulation or intravitreal Anti-VEGF treatment? Case Rep Ophthalmol 5, 231\u2013238, 10.1159\/000365865 (2014).","journal-title":"Case Rep Ophthalmol"},{"key":"BFsrep29036_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S2213-8587(14)70256-6","volume":"3","author":"B Wang","year":"2015","unstructured":"Wang, B. et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 3, 263\u2013274, 10.1016\/S2213-8587(14)70256-6 (2015).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"BFsrep29036_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA. 108.124115","volume":"53","author":"F Herse","year":"2009","unstructured":"Herse, F. et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 53, 393\u2013398, 10.1161\/HYPERTENSIONAHA. 108.124115 (2009).","journal-title":"Hypertension"},{"key":"BFsrep29036_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/hr.2014.71","volume":"37","author":"AS Sahay","year":"2014","unstructured":"Sahay, A. S. et al. A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. Hypertension Res 37, 753\u2013758, 10.1038\/hr.2014.71 (2014).","journal-title":"Hypertension Res"},{"key":"BFsrep29036_CR21","doi-asserted-by":"publisher","first-page":"e0141137","DOI":"10.1371\/journal.pone.0141137. eCollection","volume":"10","author":"HA Quigley","year":"2015","unstructured":"Quigley, H. A. et al. Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma. PLoS One. 10, e0141137. 10.1371\/journal.pone.0141137. eCollection (2015).","journal-title":"PLoS One."},{"key":"BFsrep29036_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3109\/02713681003664923","volume":"35","author":"KC Silva","year":"2010","unstructured":"Silva, K. C., Rosales, M. A., de Faria, J. B. & de Faria, J. M. Reduction of inducible nitric oxide synthase via angiotensin receptor blocker prevents the oxidative retinal damage in diabetic hypertensive rats. Curr Eye Res. 35, 519\u2013528. 10.3109\/02713681003664923 (2010).","journal-title":"Curr Eye Res."},{"key":"BFsrep29036_CR23","first-page":"2462","volume":"43","author":"NL Derevjanik","year":"2002","unstructured":"Derevjanik, N. L. et al. Quantitative assessment of the integrity of the blood- retinal barrier in mice. Invest Ophthalmol Vis Sci 43, 2462\u20132467 (2002).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFsrep29036_CR24","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1167\/iovs.11-7912","volume":"52","author":"R Robinson","year":"2011","unstructured":"Robinson, R. et al. Fluvastatin downregulates VEGF-A expression in TNF-alpha- induced retinal vessel tortuosity. Invest Ophthalmol Visual Sci 52, 7423\u20137431, 10.1167\/iovs.11-7912 (2011).","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"BFsrep29036_CR25","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cellsig.2012.02.005","volume":"24","author":"J Carbajo-Lozoya","year":"2012","unstructured":"Carbajo-Lozoya, J. et al. Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. Cell Signal 24, 1261\u20131269, 10.1016\/j.cellsig.2012.02.005 (2012).","journal-title":"Cell Signal"},{"key":"BFsrep29036_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/ j.ejphar. 2012.04.017","volume":"685","author":"S Nakamura","year":"2012","unstructured":"Nakamura, S., Tsuruma, K., Shimazawa, M. & Hara, H. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by down regulating VEGF receptor-2 expression. Eur J Pharmacol 685, 8\u201314. 10.1016\/ j.ejphar. 2012.04.017 (2012).","journal-title":"Eur J Pharmacol"},{"key":"BFsrep29036_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1757-2215-6-22","volume":"6","author":"L Song","year":"2013","unstructured":"Song, L. et al. Serum agonistic autoantibodies against type-1 angiotensin II receptor titer in patients with epithelial ovarian cancer: a potential role in tumor cell migration and angiogenesis. J Ovarian Res 6, 22, 10.1186\/1757-2215-6-22 (2013).","journal-title":"J Ovarian Res"},{"key":"BFsrep29036_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/ abbs\/gmv088","volume":"47","author":"WH Zhang","year":"2015","unstructured":"Zhang, W. H. et al. Mechanism of agonistic angiotensin II type I receptor autoantibody-amplified contractile response to Ang II in the isolated rat thoracic aorta. Acta Biochim Biophys Sin 47, 851\u2013856, 10.1093\/ abbs\/gmv088 (2015).","journal-title":"Acta Biochim Biophys Sin"},{"key":"BFsrep29036_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4103\/1596-3519.57247","volume":"8","author":"TZ Swende","year":"2009","unstructured":"Swende, T. Z. & Abwa, T. Reversible blindness in fulminating preeclampsia. Ann Afr Med 8, 189\u2013191, 10.4103\/1596-3519.57247 (2009).","journal-title":"Ann Afr Med"},{"key":"BFsrep29036_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.survophthal. 2012.08.001","volume":"58","author":"MH Errera","year":"2013","unstructured":"Errera, M. H., Kohly, R. P. & da Cruz, L. Pregnancy-associated retinal diseases and their management. Surv Ophthalmol 58, 127\u2013142. 10.1016\/j.survophthal. 2012.08.001 (2013).","journal-title":"Surv Ophthalmol"},{"key":"BFsrep29036_CR31","doi-asserted-by":"crossref","unstructured":"Saleh, L. et al. The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. Ther Adv Cardiovasc Dis. 10. pii: 1753944715624853. [Epub ahead of print] (2016).","DOI":"10.1177\/1753944715624853"},{"key":"BFsrep29036_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1095\/biolreprod. 114.126227","volume":"93","author":"Z Jiang","year":"2015","unstructured":"Jiang, Z. et al. A Role of sFlt-1 in oxidative stress and apoptosis in human and mouse pre-Eclamptic trophoblasts. Biol Reprod 93, 73. 10.1095\/biolreprod. 114.126227 (2015).","journal-title":"Biol Reprod"},{"key":"BFsrep29036_CR33","first-page":"90","volume":"58","author":"RF Chen","year":"2006","unstructured":"Chen, R. F. et al. Detection ofserum autoantibodies against AT(1A) receptor during the development of the four types of hypertensive rat models. Acta Physiol Sin 58,: 90\u201394, (2006).","journal-title":"Acta Physiol Sin"},{"key":"BFsrep29036_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/jop.2010.0123","volume":"27","author":"SK Gupta","year":"2011","unstructured":"Gupta, S. K. et al. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther, 27, 123\u2013130 (2011).","journal-title":"J Ocul Pharmacol Ther"},{"key":"BFsrep29036_CR35","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1167\/ iovs.08-3293","volume":"51","author":"J Kusari","year":"2010","unstructured":"Kusari, J., Zhou, S. X., Padillo, E., Clarke, K. G. & Gil, D. W. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest Ophthalmol Vis Sci 51, 1044\u201351. 10.1167\/ iovs.08-3293 (2010).","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep29036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29036","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep29036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:34:22Z","timestamp":1672896862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep29036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,21]]}},"alternative-id":["BFsrep29036"],"URL":"https:\/\/doi.org\/10.1038\/srep29036","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,6]]},"assertion":[{"value":"24 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29036"}}